Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 -1.83%81 3-Year EPS without NRI Growth Rate is 21.20% as of Jun. 2026, which is 7% above its 10-year median of 19.75. GuruFocus rates BSP:OFSA3 with a GF Score™ of 81/100 and a GF Value™ of R$26.34 (Fairly Valued). The stock has 3 warning signs investors should review. Among 785 Drug Manufacturers companies, Ourofino ranks better than 67.64% on this metric.
During the past 12 months, Ourofino's average EPS without NRI Growth Rate was 97.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 21.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Ourofino was 44.30% per year. The lowest was 6.00% per year. And the median was 19.75% per year.
Ourofino (BSP:OFSA3) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ourofino 3-Year EPS without NRI Growth Rate Related Terms
BSP:OFSA3 vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ourofino's 3-Year EPS without NRI Growth Rate falls into.
Ourofino 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 21.20% mean?
Ourofino (BSP:OFSA3) has a 3-Year EPS without NRI Growth Rate of 21.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ourofino and its competitors. This is near median its historical median of 19.75. Over the past decade, Ourofino's 3-Year EPS without NRI Growth Rate has ranged from 6.00 to 44.30. According to the industry distribution chart, Ourofino ranks #254 out of 785 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is Ourofino's 3-Year EPS without NRI Growth Rate too high?
Ourofino's current 3-Year EPS without NRI Growth Rate of 21.20% is near median its 10-year median of 19.75. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 44.30. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Ourofino's value of 21.20% is 120.8% above this industry median. Based on the distribution chart, Ourofino ranks #254 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ourofino has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #254 out of 785 companies for 3-Year EPS without NRI Growth Rate. This puts Ourofino in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Ourofino's value of 21.20% is 120.8% above this benchmark. Historically, Ourofino's own 3-Year EPS without NRI Growth Rate has ranged from 6.00 to 44.30 over the past decade. While the company's 10-year median is 19.75 vs. the industry median of 9.60, Ourofino has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ourofino's current 3-Year EPS without NRI Growth Rate of 21.20% is 120.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ourofino and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ourofino's current 3-Year EPS without NRI Growth Rate is 21.20%, which is near median its own 10-year median of 19.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.34, compared to a current price of R$24.70 — trading 6.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 21.20%, which is near median its 10-year median of 19.75 and 120.8% above the Drug Manufacturers industry median of 9.60. Ourofino's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current 3-Year EPS without NRI Growth Rate is 21.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be undervalued.
The current stock price of R$24.70 is trading 6.2% below its estimated GF Value™ of R$26.34.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
3-Year EPS without NRI Growth Rate: 21.20% (near median its 10-year median of 19.75)
GF Value™: R$26.34 vs. price of R$24.70 (6.2% below fair value)
Industry Position: 120.8% above the Drug Manufacturers median (#254 of 785)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
81GF Score
Get the complete analysis for BSP:OFSA3
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
